定制的金属基催化剂:针对向抗癌疗法的新平台
Maria Inês P S Leitão1, Tânia S Morais1
1Centro de Química Estrutural, Institute of Molecular Sciences and Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisbon, Portugal.
Journal of medicinal chemistry
|September 30, 2024
概括
金属复合物正在成为针对性抗癌疗法的可调节催化剂. 理性设计优化了这些催化剂的精确瘤学,提高药物输送和有效性在组合治疗.
科学领域:
- 材料科学 材料科学 材料科学
- 药用化学 医学化学
- 纳米技术 纳米技术
背景情况:
- 金属复合物为先进的抗癌治疗提供可调节的催化性能.
- 精确瘤学需要创新的策略来针对药物输送和提高治疗效率.
- 最近的进展集中在设计金属复合物以控制药物释放和现场合成.
研究的目的:
- 自2019年以来,审查用于抗癌疗法的金属催化剂的合成策略和合理设计.
- 突出金属复杂结构的优化,用于向药物释放或现场合成.
- 探索金属催化剂与生物分子,纳米结构和金属有机框架 (MOF) 的整合.
主要方法:
- 文献综述专注于金属复合体合成和癌症治疗设计方面的进展.
- 对报告金属复合体在生物环境中的催化活性研究的分析.
- 对金属基抗癌剂的体外和体内性能数据的评估.
主要成果:
- 量身定制的金属催化剂可以设计在目标部位释放或合成药物.
- 与生物分子,纳米结构和MOF结合的金属复合体显示出有希望的催化活性.
- 这些系统在体外和体内癌症模型中都已证明有效.
结论:
- 金属复合体在开发精确有效的抗癌疗法方面取得了重大进展.
- 理性设计和金属催化剂的战略性整合可以克服传统化疗的局限性.
- 对金属复合物的进一步探索有可能为瘤学中新的治疗策略提供潜力.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
14.0K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Electron Transport Chain: Complex I and II
12.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.1K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
